We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Computer Program Predicts Drug Resistance by Evaluating Whole Genome Sequencing Data

By LabMedica International staff writers
Posted on 03 Jan 2016
A software package is being evaluated in the United Kingdom that can identify a bacterium from the DNA sequence of its genome and predict which antibiotics will kill it.

The Mykrobe Predictor software for laptop and tablet computer use was developed by investigators at the University of Oxford (United Kingdom). More...
It supports Illumina Inc. (San Diego, CA, USA) instrument sequencing data as standard input. Antibiotics supported include: Beta-lactams (methicillin, penicillin), quinolones (ciprofloxacin), macrolides/lincosamides (erythromycin, clindamycin), tetracycline, aminoglycosides (gentamicin), glycopeptides (vancomycin), rifampicin, mupirocin, fusidic acid, and trimethoprim.

The program takes raw sequence data as input and generates a clinician-friendly report within three minutes on a laptop or tablet computer.

Mykrobe Predictor is currently being evaluated in three medical centers in the United Kingdom. A preliminary study comprising more than 4,500 retrospective patient samples was published in the December 21, 2015, online edition of the journal Nature Communications. Results highlighted the ability of the Mykrobe Predictor program to accurately detect antibiotic resistance in two life-threatening bacterial infections: Staphylococcus aureus (including MRSA) and Mycobacterium tuberculosis (TB).

For S. aureus, the error rates of the method were comparable to gold-standard phenotypic methods, with sensitivity/specificity of 99.1%/99.6% across 12 antibiotics. For M. tuberculosis, the method predicted resistance with sensitivity/specificity of 82.6%/98.5%. Sensitivity was lower for M. tuberculosis, probably because of limited understanding of the underlying genetic mechanisms.

The program also identified infections caused by a mixture of drug-resistant and drug-susceptible bacteria. This ability to distinguish between bacterial sub-populations gave the Mykrobe Predictor program an advantage over conventional testing in detecting resistance to second-line TB drugs.

Senior author Dr. Zamin Iqbal, a researcher in human genetics at the University of Oxford, said, "One of the barriers to making whole genome sequencing a routine part of NHS care is the need for powerful computers and expertise to interpret the masses of complex data. Our software manages data quickly and presents the results to doctors and nurses in ways that are easy to understand, so they can instinctively use them to make better treatment decisions."

Related Links:

University of Oxford
Mykrobe Predictor
Illumina Inc.



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
Automatic CLIA Analyzer
Shine i6000
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: New findings show unique pathogen‑directed antibody patterns are already present years ahead of a formal diagnosis of inflammatory bowel disease (Image Credit: iStock)

Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.